Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists Is Awarded to Vapotherm

December 4, 2020

Zenith Award from the American Association for Respiratory Care for Support of Respiratory Therapists was awarded to Vapotherm.

American Association for Respiratory Care presents the award to only six out of more than 300 manufacturers, supply organizations, and supply companies based on ranking in criteria including product quality, accessibility and helpfulness of personnel, responsiveness, service record, truth in advertising, and support of the respiratory care profession. Recipients are selected by the popular vote of AARC members in the respiratory care profession.

“We’re honored to receive the AARC Zenith Award,” said Joe Army, Vapotherm’s President and CEO. “Making our customers and their Patients a top priority is a core tenet for the Vapotherm team. This award is even more meaningful given that it is from the dedicated Respiratory Care professionals who continue to demonstrate front-line heroism during one of the most challenging years ever experienced. Thank you, Patient care colleagues, for all you and your teams are doing.”

Vapotherm increased production capacities and expanded field support teams in order to rapidly provide support during the COVID-19 pandemic. Partnering with AARC Specialty Practitioner of the Year, Felix Khusid RRT, Vapotherm launched the FELIX-1 Negative Pressure Scavenger Kit. The company also launched an open-access online learning platform, Vapotherm Academy, which has over 21,000 clinicians enrolled, in addition to its existing continuing clinical education programs.

AARC established the AARC Zenith Award in 1989 and this is the first year AARC selected Vapotherm as a recipient of the award. AARC announced the 2020 AARC Zenith Award recipients by live-stream in conjunction with the virtual 66th International Respiratory Congress on December 3rd.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”